We rebrand our shape, logo and domain
Start for free.png)
ENNEDY SPACE CENTER (FL), October 24, 2018 –The International Space Station (ISS) U.S. National Laboratory, the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), today announced a series of project awards stemming from a funding opportunity on human physiology and disease onboard the orbiting laboratory.
SpacePharma SA selected ISIS – Innovative Solutions In Space B.V. to build the platform and integrate the payload for their next mission, DIDO-3, with support for satellite commissioning after launch. The agreement is a continuation of a fruitful cooperation to realize SpacePharma’s previous satellite, named DIDO-2, which was the proof of concept mission to test miniaturized end-to-end pharmaceutical laboratory in space, allowing microgravity conditions.
Organs-on-chips technology are about to take flight, literally. The National Center for Advancing Translational Sciences and the Center for the Advancement of Science in Space co-granted funding last year to launch five research teams’ chips into space. The projects will be shuttled over the span of two launches, the first in November and the next in February.
NCATS has partnered with the Center for the Advancement of Science in Space (CASIS) to collaborate on refining tissue chip technology for biomedical research use at the International Space Station U.S. National Laboratory (ISS-NL).
Huge honor! SpacePharma has been selected for Red Herring's top 100 companies in North America!
A startup of Courgenay launched in 2012 to conquer space. Last Wednesday, SpacePharma positioned in orbit, thanks to an Indian launcher, a nanosatellite of research. This miniaturized laboratory is a small revolution. For the first time, according to Martin Aegbi, the CEO, laboratories will be able to carry out their tests, at a lower cost, directly, without going through the ISS, and in a very short time.
Research goes airborne: The UZH Space Hub is holding its first research flight campaign from 11 to 13 June. An airbus performing parabolic flights will take off from the military airfield in Dübendorf. In addition, a zeppelin will be used to investigate how to discover plastic in water from above using special image sensors. This could help to detect plastic pollution in the world’s seas.
MILAN - The first 'extraterrestrial' factories are getting ready to become reality: as early as 2019 the first in-orbit tests will begin to develop the technologies necessary to produce in gravity-free conditions on small Earth-controlled satellites.
Spacepharma specializes in medical experiments in microgravity, that is approximate weightlessness. This can accelerate research processes for new drugs or vaccines. In weightlessness, crystals, proteins, liquids and human genomes react differently than on Earth.
Fast Company's Top 10 lists recognize pioneering companies across 36 categories, from artificial intelligence to wellness. More than three dozen Fast Company editors, reporters, and contributors surveyed thousands of companies to create these lists. The ranking recognizes companies that exemplify the best in business and innovation in their respective fields.
Once again SpacePharma is very proud to be nominate as second place for innovation in Space. Now it is your turn to use this great machine for the benefits of mankind.... One more small dosage, few more unique molecules will shape our future. Cheers for better life, better food, better science using microgravity conditions.
Space has become an increasingly attractive destination for research, manufacturing and more, as its microgravity environment offers a unique platform for scientific exploration. Microgravity causes changes in biological systems and alters fundamental physical phenomena, enabling novel experiments.
SpacePharma offers its customers to carry out microgravity experiments with remote controlled laboratories.
On the sidelines of the Ilan Ramon conference in Tel Aviv on space, Italy and Israel signed an agreement to enable the creation of a joint micro-gravity laboratory. The announcement was made by the Italian embassy, which noted that - in February 2019 - there may be the launch from an Italian-produced Vega shuttle of a space module the size of an electric bicycle battery made by the Israel-based company SpacePharma.
Flow chemistry in space–a unique opportunity to perform extraterrestrial research For successful deep space exploration, a vast amount of chemistry-related challenges has to be overcome. In the last two decades, flow chemistry has matured enough to take the lead in performing chemical research in space. This perspective article summarizes the state of the art of space chemistry, analyzes the suitability of flow chemistry in extraterrestrial environment, and discusses some of the challenges and opportunities in space chemistry ranging from establishing an end-to-end microfactory to asteroid mining. For the full PDF article. For more information about SpacePharma, visit www.space4p.com
Peoples Awards 2017. Rankings - Leaders & Companies For more information about SpacePharma, visit www.space4p.com
NewSpace People - SpacePharma Ranked 11 out of Top 1,000 companies in 2017 For more information about SpacePharma, visit www.space4p.com
Florida Governor, Rick Scott, honored SpacePharmas CEO & Founder a Golden Business medal for SpacePharma's activity in Florida. For more information about SpacePharma, visit www.space4p.com.
Fast Company - SpacePharma’s Microgravity Labs Augur Drug Breakthroughs Of The Future
For more information, visit www.space4p.com.
Docking of the OA8 with SpacePharma's Nexus Lab inside to the ISS
For more information, visit www.space4p.com.
Spacepharma's Nexus Launch to the ISS
For more information, visit www.space4p.com.
PRESS RELEASE – Space Florida News ; Space Florida and Israel Innovation Authority Announce Fourth Round Winners of Innovation Partner Funding ; Micro – gRx/Sanford Burnham Preby’s Medical Discovery Institute (Lake Nona, FL) & SpacePharma (Israel)
For more information, visit www.space4p.com.
PRESS RELEASE CBInsights - July 6 2017, Frontier Health: 11 Startups Pioneering VR, Drones, Space Tech, Brain-Hacking, And More To Advance Medical Care. For more information, visit www.space4p.com.
PRESS RELEASE The Washington Post - March 18 2017 A tissue-box-size lab is circling the Earth conducting tiny experiments. For more information, visit www.space4p.com.
SpacePharma establishes communications with its first nanosatellite.
Company inching closer to offering scientific community a third viable platform for affordable access to microgravity
COURGENAY, Switzerland – Officials with SpacePharma SA, a world leader in providing simplified, high-value microgravity services, today issued the following statement regarding its orbiting nanosatellite, DIDO, which was one of 104 satellites launched on Feb. 15 aboard Indian Space Research Organization’s PSLV-C37 rocket:
“Today, we established a successful communications link with DIDO, SpacePharma’s nanosatellite equipped with mGnify, our proprietary miniaturized, end-to-end laboratory that allows researchers to remotely control vital scientific experiments anywhere from Earth,” said Yossi Yamin, founder of SpacePharma SA. “Everything on board DIDO appears to be working properly. We look forward to fully activating mGnify in the coming weeks and launching a suite of scientific experiments for our research customers. At that point, we will officially have three viable platforms – ground simulators, parabolic flights and nanosatellites – for achieving affordable access to microgravity.”
About SpacePharma SA SpacePharma SA is a world leader in providing simplified, high-value, end-to-end microgravity services and solutions for research. Headquartered in Switzerland, the company’s diverse team of professionals also operate an R&D division in Israel and its U.S. subsidiary based in Palo Alto, Calif. For more information, visit www.space4p.com.
MEDIA CONTACT: Melissa Wren Griffin Communications Group (281) 335-0200; melissa@griffincg.com
SpacePharma SA completes first step in securing new platform for affordable access to microgravity
BASEL, Switzerland – Officials with SpacePharma SA, a world leader in providing simplified, high-value microgravity services, today issued the following statement on the successful launch of the Indian Space Research Organisation’s PSLV-C37 rocket, which carried SpacePharma’s DIDO nanosatellite – one of 101 nanosatellites on board:
“Today’s launch marks an important milestone in SpacePharma’s quest to offer researchers affordable access to microgravity through multiple platforms,” said Yossi Yamin, founder of SpacePharma SA. “The rocket carried our newest platform, a nanosatellite named DIDO. This nanosatellite is equipped with mGnify, our proprietary miniaturized, end-to-end laboratory that allows researchers to remotely control vital scientific experiments anywhere from Earth. We plan to establish communication with DIDO in a few days, which then sets the stage for full activation of mGnify shortly thereafter. Once fully activated, our science customers will be able to fully control their on-board experiments and receive valuable scientific data directly on the device of their choice.”
About SpacePharma SA SpacePharma SA is a world leader in providing simplified, high-value, end-to-end microgravity services and solutions for research. Headquartered in Switzerland, the company’s diverse team of professionals also operate an R&D division in Israel and its U.S. subsidiary based in Palo Alto, Calif. For more information, visit www.space4p.com.
MEDIA CONTACT: Melissa Wren Griffin Communications Group (281) 335-0200; melissa@griffincg.com
10... 9... 8...
We're launching today! DIDO - our satellite, has been placed inside the Indian rocket PSLV-C37. In a few hours it'll be sent off to space together with a record number of 100 other nano-satellites.
You're welcome to watch the live feed of the launch through the Indian Space Research Organization website.
We have just launched our new website, and we are soon launching DIDO, our first satellite (currently scheduled for Feb 15th, 03:58:00 GMT). Stay tuned for more updates!
On October 22, our team has successfuly flown a few microgravity experiments on-board a parabolic flight which took place in Switzerland. Not only did interesting science run in our miniturized lab, but we have also demonstrated some of the new technology which will be part of our future generation lab Read more
SpacePharma has opened offices in Palo Alto, California. Check out our press release
Geektime has selected SpacePharma as 1 of 10 space companies to watch in 2016/2017 Beyond SpaceX: 10 space companies to watch in 2016 & 2017
CB Insights has chosen SpacePharma as 1 of the 55 most innovative, game-changing companies in the world! Check it out: CB Insights - Game Changers
Although VEGA launch scrubbed again on June 28th, Lab-team at SpacePharma couldn't leave you without the information released for the experiments on board.
#DIDO-3 is keeping all reagents, bacterias and more under safe cooling condition awaiting the mission to start. #vega
DIDO-3 # is right around the corner!
Despite the COVID-19 known also as the coronavirus pandemic, DIDO-3 will fly soon.
ASI,ISA,AVIO,SAB and of course ISIS have all shaked hands to this space medics mission to promote our health on earth.
Next week we will start to introduce you with the scientist's from Italy and Israel who worked hard to define their research on orbit using DIDO-3.
Cheers to you all.
